HRP20110083T1 - Uporaba agomelatina u proizvodnji lijeka za liječenje bipolarnih poremećaja - Google Patents

Uporaba agomelatina u proizvodnji lijeka za liječenje bipolarnih poremećaja Download PDF

Info

Publication number
HRP20110083T1
HRP20110083T1 HR20110083T HRP20110083T HRP20110083T1 HR P20110083 T1 HRP20110083 T1 HR P20110083T1 HR 20110083 T HR20110083 T HR 20110083T HR P20110083 T HRP20110083 T HR P20110083T HR P20110083 T1 HRP20110083 T1 HR P20110083T1
Authority
HR
Croatia
Prior art keywords
treatment
pharmaceutically acceptable
intended
pharmaceutical preparations
hydrates
Prior art date
Application number
HR20110083T
Other languages
English (en)
Croatian (hr)
Inventor
De Bodinat Christian
Mocaer Elisabeth
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110083(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HRP20110083T1 publication Critical patent/HRP20110083T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HR20110083T 2005-04-20 2011-02-02 Uporaba agomelatina u proizvodnji lijeka za liječenje bipolarnih poremećaja HRP20110083T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Publications (1)

Publication Number Publication Date
HRP20110083T1 true HRP20110083T1 (hr) 2011-03-31

Family

ID=35311309

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110083T HRP20110083T1 (hr) 2005-04-20 2011-02-02 Uporaba agomelatina u proizvodnji lijeka za liječenje bipolarnih poremećaja

Country Status (41)

Country Link
US (1) US7947743B2 (de)
EP (1) EP1714647B1 (de)
JP (2) JP4580364B2 (de)
KR (2) KR100835451B1 (de)
CN (2) CN102038669A (de)
AP (1) AP2656A (de)
AR (1) AR057277A1 (de)
AT (1) ATE491443T1 (de)
AU (1) AU2006201655B2 (de)
BR (1) BRPI0601285A8 (de)
CA (1) CA2544136C (de)
CR (1) CR9426A (de)
CY (1) CY1111257T1 (de)
DE (1) DE602006018822D1 (de)
DK (1) DK1714647T3 (de)
EA (1) EA013462B1 (de)
ES (1) ES2357901T3 (de)
FR (1) FR2884714B1 (de)
GE (1) GEP20094651B (de)
GT (1) GT200600141A (de)
HR (1) HRP20110083T1 (de)
IL (1) IL186373A (de)
JO (1) JO2666B1 (de)
MA (1) MA28266A1 (de)
ME (1) ME01951B (de)
MY (1) MY143171A (de)
NO (1) NO336010B1 (de)
NZ (1) NZ546630A (de)
PE (1) PE20061337A1 (de)
PL (1) PL1714647T3 (de)
PT (1) PT1714647E (de)
PY (1) PY0610113A (de)
RS (1) RS51659B (de)
SG (1) SG126868A1 (de)
SI (1) SI1714647T1 (de)
TN (1) TNSN07364A1 (de)
TW (2) TWI318115B (de)
UA (1) UA83681C2 (de)
UY (1) UY29470A1 (de)
WO (1) WO2006111653A1 (de)
ZA (1) ZA200603160B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
WO2008137461A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (de) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarker zur Vorhersage der langfristigen Remission bei Depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
US7122576B2 (en) * 2001-02-27 2006-10-17 Plata-Salaman Carlos R Carbamate compounds for use in preventing or treating bipolar disorder
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality

Also Published As

Publication number Publication date
TWI318115B (en) 2009-12-11
CA2544136A1 (fr) 2006-10-20
CY1111257T1 (el) 2015-08-05
AR057277A1 (es) 2007-11-28
EP1714647B1 (de) 2010-12-15
HK1093906A1 (en) 2007-03-16
GEP20094651B (en) 2009-03-25
FR2884714A1 (fr) 2006-10-27
AP2656A (en) 2013-05-07
DK1714647T3 (da) 2011-03-07
BRPI0601285A (pt) 2006-12-19
DE602006018822D1 (de) 2011-01-27
TW200716083A (en) 2007-05-01
US7947743B2 (en) 2011-05-24
CN1853619A (zh) 2006-11-01
NZ546630A (en) 2007-09-28
MA28266A1 (fr) 2006-11-01
CN1853619B (zh) 2011-02-02
BRPI0601285A8 (pt) 2021-03-30
NO336010B1 (no) 2015-04-20
CN102038669A (zh) 2011-05-04
TNSN07364A1 (en) 2008-12-31
TW200940049A (en) 2009-10-01
AP2007004212A0 (en) 2007-10-31
JP2010280699A (ja) 2010-12-16
MY143171A (en) 2011-03-31
PL1714647T3 (pl) 2011-05-31
US20060240127A1 (en) 2006-10-26
ATE491443T1 (de) 2011-01-15
PT1714647E (pt) 2011-01-14
EP1714647A1 (de) 2006-10-25
ME01951B (de) 2011-10-31
JP5341037B2 (ja) 2013-11-13
WO2006111653A1 (fr) 2006-10-26
GT200600141A (es) 2006-11-22
ES2357901T3 (es) 2011-05-03
FR2884714B1 (fr) 2011-05-06
EA200600600A1 (ru) 2006-10-27
ZA200603160B (en) 2007-06-27
AU2006201655A1 (en) 2006-11-09
CA2544136C (fr) 2012-02-21
IL186373A (en) 2012-06-28
JO2666B1 (en) 2012-06-17
UY29470A1 (es) 2006-05-31
UA83681C2 (uk) 2008-08-11
JP4580364B2 (ja) 2010-11-10
JP2006316056A (ja) 2006-11-24
RS51659B (sr) 2011-10-31
KR20080028389A (ko) 2008-03-31
KR100835451B1 (ko) 2008-06-09
SI1714647T1 (sl) 2011-03-31
PY0610113A (es) 2011-01-03
IL186373A0 (en) 2008-08-07
KR20060110803A (ko) 2006-10-25
AU2006201655B2 (en) 2009-04-23
PE20061337A1 (es) 2007-01-27
EA013462B1 (ru) 2010-04-30
CR9426A (es) 2008-02-21
SG126868A1 (en) 2006-11-29
NO20061705L (no) 2006-10-23

Similar Documents

Publication Publication Date Title
HRP20250148T1 (hr) Specifični triptamini za uporabu u liječenju poremećaja raspoloženja
MX2009008228A (es) N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide.
ES2542847T3 (es) Formulaciones que comprenden capsaicina, un anestésico local y/o un agente antipruriginoso para el tratamiento del dolor
CO5840252A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada
MX2022014444A (es) Sal de malato de n-(4-{[6,7-bis(metiloxi) quinolin-4-il] oxi}fenil)-n'-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
GEP20043160B (en) Biaryl Ether Derivatives, Pharmaceutical Compositions Containing Them and Their Use as Monoamine Reuptake Inhibitors
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
MX2022016230A (es) Clorhidrato de (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-nmetilm etanamina cristalino y formulaciones de las mismas.
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
RU2015115064A (ru) Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
WO2008101907A3 (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
HRP20110083T1 (hr) Uporaba agomelatina u proizvodnji lijeka za liječenje bipolarnih poremećaja
NZ593994A (en) Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as kcnq2/3 modulators
HRP20110370T1 (hr) Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
AR056063A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos del sueno en el paciente deprimido
EA201070315A1 (ru) Жидкая лекарственная форма конъюгата
HRP20120344T1 (hr) N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije
HRP20100680T1 (hr) Upotreba agomelatina za dobivanje lijeka u cilju lijecenja periventrikularne leukomalacije
TW200507853A (en) Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
AR081007A1 (es) Combinacion farmaceutica caracterizada porque comprende ibuprofeno y l-arginina
EA201592297A1 (ru) Композиции агомелатина, содержащие агомелатин в форме сокристаллов
JP2005068035A (ja) 慢性疼痛治療用外用剤
JP5451020B2 (ja) 外用関節痛治療剤
HRP20080535T3 (en) New association of agomelatine and a noradrenalin reuptake inhibitor, and pharmaceutical compositions containing them